Virus-specific CD4(+) T cells: ready for direct attack

CD4(+) T cells are classically thought to orchestrate adaptive immune responses. But recent studies demonstrate that they can also kill infected cells directly. A new paper shows that highly efficient processing of Epstein Barr virus (EBV) glycoproteins for presentation on MHC class II makes virus-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Heller, Kevin N., Gurer, Cagan, Münz, Christian
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2006
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118265/
https://www.ncbi.nlm.nih.gov/pubmed/16549599
http://dx.doi.org/10.1084/jem.20060215
_version_ 1782140986643709952
author Heller, Kevin N.
Gurer, Cagan
Münz, Christian
author_facet Heller, Kevin N.
Gurer, Cagan
Münz, Christian
author_sort Heller, Kevin N.
collection PubMed
description CD4(+) T cells are classically thought to orchestrate adaptive immune responses. But recent studies demonstrate that they can also kill infected cells directly. A new paper shows that highly efficient processing of Epstein Barr virus (EBV) glycoproteins for presentation on MHC class II makes virus-transformed B cells susceptible to lysis by CD4(+) T cells. Thus, antiviral vaccines should aim to stimulate both helper and cytolytic CD4(+) T cells.
format Text
id pubmed-2118265
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21182652007-12-13 Virus-specific CD4(+) T cells: ready for direct attack Heller, Kevin N. Gurer, Cagan Münz, Christian J Exp Med Commentaries CD4(+) T cells are classically thought to orchestrate adaptive immune responses. But recent studies demonstrate that they can also kill infected cells directly. A new paper shows that highly efficient processing of Epstein Barr virus (EBV) glycoproteins for presentation on MHC class II makes virus-transformed B cells susceptible to lysis by CD4(+) T cells. Thus, antiviral vaccines should aim to stimulate both helper and cytolytic CD4(+) T cells. The Rockefeller University Press 2006-04-17 /pmc/articles/PMC2118265/ /pubmed/16549599 http://dx.doi.org/10.1084/jem.20060215 Text en Copyright © 2006, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Commentaries
Heller, Kevin N.
Gurer, Cagan
Münz, Christian
Virus-specific CD4(+) T cells: ready for direct attack
title Virus-specific CD4(+) T cells: ready for direct attack
title_full Virus-specific CD4(+) T cells: ready for direct attack
title_fullStr Virus-specific CD4(+) T cells: ready for direct attack
title_full_unstemmed Virus-specific CD4(+) T cells: ready for direct attack
title_short Virus-specific CD4(+) T cells: ready for direct attack
title_sort virus-specific cd4(+) t cells: ready for direct attack
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118265/
https://www.ncbi.nlm.nih.gov/pubmed/16549599
http://dx.doi.org/10.1084/jem.20060215
work_keys_str_mv AT hellerkevinn virusspecificcd4tcellsreadyfordirectattack
AT gurercagan virusspecificcd4tcellsreadyfordirectattack
AT munzchristian virusspecificcd4tcellsreadyfordirectattack

Ejemplares similares